Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib versus interferon alfa-2a as first-line treatment for unresectable or metastatic renal cell carcinoma
2005-000544-86Phase 2Completed
- Sponsor
- Bayer
- Start
- Apr 2005
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in renal cell carcinoma (RCC) comparing Sorafenib with Interferon alfa-2a (2 arms). Primary endpoint: Progression-free survival. Started Apr 2005; status: completed.
02
Drugs
sorafenibinterferon alfa-2a
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2005-000544-86.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000544-86.